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Tissue-bath experiments
Isolated smooth muscle strips, maintained in temperature controlled Krebs buffer, were
mounted between two platina electrodes attached to the mounting hook in glass tissue
bath containers and connected to a force transducer to record smooth muscle
contractions (Fig. 1). Four smooth muscle preparations were used for the functional
screening of candidate bioactive peptides (Table 1).
Twenty-five candidate bioactive peptides were selected, based on a multi-criteria decision strategy, and screened in tissue organ bath experiments using four
isolated preparations. Three peptides induced significant alterations of smooth muscle contractions: SBO121 and SBO215/215_7 (gpI) and SBO 291(mVD).
However, it was observed that SBO215_7 (>95% purity) did not influence smooth muscle contractions, contrary to “crude” SBO215_7 peptide quality.
Therefore, analytical controls are crucial to establish the correct peptide structure responsible for the bioactivity and to control the peptide purity.
Peptides show great pharmaceutical potential as active drugs and diagnostics in several clinical areas such as endocrinology, obstetrics or oncology [1]. The
search towards novel lead-peptides with a biological function has thus attracted renewed interest. Within a collaborative, multidisciplinary approach, several
new peptides were identified with the potential of being new drugs or serving as a basis towards new drugs. Twenty-five peptides, selection based on a multi-
criteria decision strategy, were tested in tissue baths using different smooth muscle preparations. A positive bioactivity was confirmed if a significant alteration
of the smooth muscle contractility was induced by the addition of the investigated peptides. Analytical controls to establish the correct peptide structure
responsible for the bioactivity have been performed as well, stressing the importance of purity control.
Analytical control of bioactive peptides
The purity of peptides used for functionality
testing ranged from crude to 98%. Stock
and tissue bath samples of bioactive
peptides were analyzed using HPLC UV-
MS to identify the correct peptide structure
responsible for the bioactivity. A C18
reversed phase column with gradient
program (acetonitril/water mixture) and UV
detection was used for quantification, while
HPLC-ESI/iontrap MSn was used for
identification purposes [1].
EXPERIMENTAL 
Table 1: Isolated muscle preparations; experimental conditions.
Isolated preparations Guinea pig ileum Guinea pig trachea Mouse vas deferens Rat aortic ring
Pre-stretch (g) 0.7 2.0 0.2 2.0
Krebs buffer Mg2+ containing Mg2+ containing Mg2+ free Mg2+ containing
TKrebs buffer (°C) 36 36 31 36
Electrical stimulation Yes No Yes No
Fig.1: Tissue bath 
model with isolated 
smooth muscle strip.
Twenty-five peptides were screened in four isolated smooth muscle preparations, three peptides were able to induce significant alterations of smooth muscle
contractions: SBO121 and SBO215/215_7 (both in guinea pig ileum, gpI) and SBO291 (in mouse vas deferens, mVD) (Fig. 2).
SBO215_7 (>95% purity)
SBO121
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Fig. 3: SBO121 inhibition of EFS 
induced contractions.
1g 1min
Addition of SBO121 inhibited electrical induced smooth
muscle contractions (Fig. 2-3, relative to EFS induced
contractions before), while SBO215 induced baseline
contractions without significant alterations of the magnitude
of the EFS induced contractions in gpI. However, no baseline
contractions were observed with pure SBO215_7 peptide.
SBO291 exerts similar actions as SBO215, but on mVD.
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Fig. 2: Representative tracings showing the effect of SBO121 and SBO215/215_7 in 
gpI and SBO291 in mVD (left), and the apposite MS spectra (right). The repetitive 
contractions were induced by electrical field stimulation (EFS), the non-stimulated 
contractions by acetylcholine (Ach) and phenylephrine (PE). 
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